Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

New NCCN program recognizes organizations supporting coverage for clinical trials and appropriate off-label drug usage.

[No authors listed]

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 3:vii-ix. No abstract available.

PMID:
21357669
2.

Prevalence of off-label use of oral oncolytics at a community cancer center.

Kalis JA, Pence SJ, Mancini RS, Zuckerman DS, Ineck JR.

J Oncol Pract. 2015 Mar;11(2):e139-43. doi: 10.1200/JOP.2014.001354. Epub 2015 Jan 20.

PMID:
25604593
3.

Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.

Mailankody S, Prasad V.

Oncologist. 2016 Sep;21(9):1031-2. doi: 10.1634/theoncologist.2016-0086. Epub 2016 Jul 8. No abstract available.

4.

Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience.

Lerose R, Musto P, Aieta M, Papa C, Tartarone A.

Eur J Clin Pharmacol. 2012 May;68(5):505-12. doi: 10.1007/s00228-011-1173-6. Epub 2011 Dec 14. Review.

PMID:
22166932
5.
6.

Oncology trial design: More accurately and efficiently advancing the field.

Hohl RJ.

Clin Pharmacol Ther. 2015 May;97(5):430-2. doi: 10.1002/cpt.94. No abstract available.

PMID:
25684240
7.

The complexity of covering off-label use for a multitude of oncology regimens.

Mehr SR.

Am J Manag Care. 2012 Dec;18(5 Spec No.):SP242-7. Review. No abstract available.

PMID:
23301714
8.

Off-label use of anti-cancer drugs in India: to be or not to be!

Gota V, Patial P.

J Cancer Res Ther. 2011 Jan-Mar;7(1):35-9. doi: 10.4103/0973-1482.80455.

9.

State insurance mandates and off-label use of chemotherapy.

Smieliauskas F, Sharma H, Hurley C, de Souza JA, Shih YT.

Health Econ. 2018 Jan;27(1):e55-e70. doi: 10.1002/hec.3537. Epub 2017 Jul 20.

PMID:
28726348
10.

Projects seek hidden effects of cancer drugs.

Ledford H.

Nature. 2014 Dec 4;516(7529):21-2. doi: 10.1038/516021a. No abstract available.

PMID:
25471862
11.

Advances in drug development: off-label drug utilization in oncology.

de Souza JA.

Clin Adv Hematol Oncol. 2011 Jun;9(6):473-5. No abstract available.

PMID:
21841748
12.

Reflections about off-label use of anticancer drugs.

Tartarone A, Lerose R, Aieta M.

Ther Drug Monit. 2012 Oct;34(5):604. doi: 10.1097/FTD.0b013e318268478d. No abstract available.

PMID:
22972541
13.

Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.

Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB.

J Clin Oncol. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19.

14.

Off-label drug use in oncology: a systematic review of literature.

Saiyed MM, Ong PS, Chew L.

J Clin Pharm Ther. 2017 Jun;42(3):251-258. doi: 10.1111/jcpt.12507. Epub 2017 Feb 5. Review.

PMID:
28164359
15.

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives.

Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, Goldberg SE, Gottlieb S, Johnson PE, Lyman GH, Markus R, Matulonis UA, Reinke D, Li EC, DeMartino J, Larsen JK, Hoffman JM.

J Natl Compr Canc Netw. 2011 Sep;9 Suppl 4:S1-22.

PMID:
21976013
16.

Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.

Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK.

Pharmacotherapy. 2017 Sep;37(9):1043-1051. doi: 10.1002/phar.1917. Epub 2017 Apr 2.

PMID:
28235141
17.

What drives diffusion of new cancer therapies?

Schmidt C.

J Natl Cancer Inst. 2015 Jun 1;107(6):djv162. doi: 10.1093/jnci/djv162. Print 2015 Jun. No abstract available.

PMID:
26032609
18.

Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.

Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM).

Tumori. 2009 Nov-Dec;95(6):647-51.

PMID:
20210223
19.

American Society of Clinical Oncology Developing First Clinical Trial.

Brower V.

J Natl Cancer Inst. 2015 Nov 4;107(11):djv356. doi: 10.1093/jnci/djv356. Print 2015 Nov. No abstract available.

PMID:
26538625
20.

Improving evidence developed from population-level experience with targeted agents.

McClellan MB, Daniel GW, Dickson D, Perlmutter J, Berger DP, Miller V, Nussbaum S, Malin J, Romine MH, Schilsky RL.

Clin Pharmacol Ther. 2015 May;97(5):478-87. doi: 10.1002/cpt.90. Epub 2015 Apr 3. Review.

PMID:
25676878

Supplemental Content

Support Center